New drug tested for Tough-to-Treat blood cancers
Disease control
Terminated
This study tested a new drug called ASTX660 for people with T-cell lymphoma that has returned or not improved with other treatments. The main goals were to find a safe dose and see how well the drug worked. The trial was small and ended early, so it was a first step in understand…
Phase: PHASE1, PHASE2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC